Neoplasms

All Conditions

Respiratory Tract (Lung and Bronchial) Diseases

Digestive System Diseases

Rare Diseases

Adenocarcinoma

Carcinoma, Non-Small-Cell Lung

Stomach Neoplasms

Sarcoma

Lung Neoplasms

Sarcoma, Alveolar Soft Part

Neoplasms by Histologic Type

Neoplasms, Connective and Soft Tissue

Stomach Cancer

Soft Tissue Sarcoma

Alveolar Soft Part Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Hematinics

Bevacizumab

Liver Extracts

Ramucirumab

Futibatinib

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

AB122 will be given in participants with advanced or metastatic solid tumor.

AB122 will be given in combination with TAS-116 in participants with pancreatic ductal adenocarcinoma.

AB122 will be given in combination with TAS-116 in participants with unresectable metastatic MSS/pMMR CRC without liver metastases.

AB122 will be given in combination with TAS-116 in participants with unresectable metastatic non-squamous NSCLC without actionable gene alterations.

AB122 will be given in combination with TAS-120 in participants with unresectable metastatic NSCLC with PD-L1 high expression and without actionable gene alterations.

AB122 will be given in combination with TAS-115 in participants with unresectable metastatic NSCLC without actionable gene alterations.

AB122 will be given in combination with TAS-115 in participants with unresectable metastatic ASPS, in those who received or no prior regimen for advanced disease.

AB122 will be given in combination with TAS-102 and Ramucirumab in participants with unresectable or recurrent gastric cancer or gastroesophageal junction cancer.

AB122 will be given in combination with TAS-102 and Bevacizumab in participants with unresectable metastatic CRC.

AB122 will be administered with 240 mg/body given by infusion over 60 minutes Q2W.

AB122

AB122 will be administered with 360 mg/body given by infusion over 60 minutes Q3W.

TAS-116 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hour after eating.

TAS-116

AB122 will be administered with 360 mg/body given by infusion over 60 minutes every 3 weeks.

TAS-120 will be administered orally once daily (QD) on an empty stomach at least 1 hour before or 2 hours after eating.

TAS-120

TAS-115 will be administered orally in 5-day on and 2-day off schedule on an empty stomach at least 1 hour before or 2 hours after eating.

TAS-115

AB122 will be administered with 240 mg/body given by infusion over 60 minutes every 2 weeks.

TAS-102 will be administered orally twice daily at a dose calculated based on body surface area (BSA) within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

TAS-102

Ramucirumab will be administered by infusion at a dose calculated using the body weight over approximately 60 minutes every 2 weeks.

TAS-102 will be administered orally twice daily at a dose calculated based on BSA within 1 hour after morning and evening meals for 5 days, a week with 2 days rest for 2 weeks, followed by a 14-day rest, repeated every 4 weeks.

Bevacizumab will be administered by infusion at a dose calculated using the body weight over approximately 90 minutes every 2 weeks.

Drug Information Center

Taiho Pharmaceutical Co., Ltd.

This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.

AB122 Platform Study

Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors

Data will not be shared according to the Sponsor policy on data sharing. Taiho policy on data sharing may be found at https://www.taiho.co.jp/en/science/policy/clinical_trial_information_disclosure_policy/index.html.

Spots Global Cancer Trial Database for AB122 Platform Study

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial